SUCCESS WITH LESS INVASIVE VENTILATION

CUROSURF® (poractant alfa) Intratracheal Suspension administration facilitates transition from mechanical ventilation (MV)

The table below details the studies in which CUROSURF® (poractant alfa) Intratracheal Suspension was used in conjunction with less invasive ventilation. In each study, the addition of CUROSURF to nCPAP or NIPPV helped a majority of infants stay on less invasive ventilation, avoiding the need for reintubation or subsequent MV.1-5

Less invasive ventilation success rates across studies with CUROSURF

In the Verder 1994 study, patients receiving CUROSURF® (poractant alfa) followed by NCPAP experienced significantly higher success rates vs NCPAP alone.1

Later studies demonstrated higher success rates when CUROSURF was administered early vs late.3,4

High success rates demonstrated when CUROSURF administered via the INSURE method (early intubation, surfactant administration, and rapid extubation to NCPAP).3,4

CLINICAL STUDY N* GESTATIONAL AGE VENTILATION STRATEGY INDICATION
FOR MV
SUCCESS WITH
LESS INVASIVE VENTILATION
Verder H, et al. 1994 1 (pilot) 73 25–35 weeks NCPAP
vs
NCPAP + surfactant
a/APO2 <0.15 57% of infants treated with CUROSURF did not require subsequent MV
Verder H, et al. 1999 2 60 25–29 weeks NCPAP + early surfactant administration
vs
NCPAP + late surfactant administration§
a/APO2 ≤0.21
to 0.15
79% of infants treated with early administration of CUROSURF did not require subsequent MV
Dani C, et al.
2004 3
27 Early surfactant administration + rapid extubation to NCPAP (INSURE): 29.0 ± 2.2 weeks MV + surfactant: 28.3 ± 1.32 weeks INSURE||
vs
MV + surfactant
FiO2 >0.50 100% of infants treated with early CUROSURF administration followed by rapid extubation did not require subsequent MV
0% of infants in INSURE group required more than one dose of CUROSURF
Bohlin K, et al.
2007 4 (retrospective)
420 27–34 weeks INSURE
vs
MV + surfactant
a/APO2 0.22 81% of infants treated with early CUROSURF administration followed by rapid extubation did not require subsequent MV
17% of infants in INSURE group required more than one dose of CUROSURF
Ramanathan R,
et al. 2012 5
110 26–30 weeks NIPPV
vs
SIMV with extubation to NCPAP
FiO2 >0.60 83% of infants treated with CUROSURF and NIPPV did not require subsequent MV

*Total number of infants randomized. Success with less invasive ventilation is defined as no further need to reintubate for subsequent MV. NCPAP = nasal continuous positive airway pressure. §Late surfactant administration was defined as after FiO2 has risen to 0.57–0.77.2 ||INSURE = intubation, surfactant, rapid extubation. NIPPV = nasal intermittent positive pressure ventilation.

In the Verder 1994 study, patients receiving CUROSURF® (poractant alfa) followed by NCPAP experienced significantly higher success rates vs NCPAP alone.1

Later studies demonstrated higher success rates when CUROSURF was administered early vs late.3,4

High success rates demonstrated when CUROSURF administered via the INSURE method (early intubation, surfactant administration, and rapid extubation to NCPAP).3,4